• 1. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 2. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 3. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 4. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylacetamides

Compound Introduction: CAS No 115199-84-3 and Product Name: ICI 199441

The compound with the chemical identifier CAS No 115199-84-3 and the product name ICI 199441 represents a significant advancement in the field of pharmaceutical chemistry. This compound has garnered considerable attention due to its unique structural properties and its potential applications in medicinal chemistry. The molecular framework of this compound exhibits a high degree of complexity, which contributes to its multifaceted biological activities. Recent studies have highlighted its role as a promising candidate for further exploration in therapeutic interventions.

In the realm of chemical biology, the investigation of novel compounds with distinct pharmacological profiles is crucial for the development of next-generation therapeutics. The structural elucidation of CAS No 115199-84-3 has revealed an intricate arrangement of functional groups that are believed to contribute to its remarkable biological efficacy. This compound has been extensively studied for its potential in modulating various cellular pathways, particularly those involved in inflammation and immune response. The findings from these studies suggest that this molecule could serve as a valuable scaffold for designing novel drugs that target chronic inflammatory diseases.

One of the most intriguing aspects of ICI 199441 is its ability to interact with multiple targets within the same biological pathway. This polypharmacicity is a desirable trait in drug development, as it can lead to synergistic effects that enhance therapeutic outcomes. Recent research has demonstrated that this compound exhibits potent inhibitory activity against several enzymes implicated in the pathogenesis of neurodegenerative disorders. The molecular mechanism by which it exerts its effects appears to involve precise modulation of protein-protein interactions, thereby disrupting disease-causing signaling cascades.

The synthesis and characterization of CAS No 115199-84-3 have been subjects of intense interest among synthetic chemists. The development of efficient synthetic routes has enabled researchers to produce this compound in sufficient quantities for preclinical testing. Advanced spectroscopic techniques, such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS), have been instrumental in confirming the structural integrity of this molecule. These analytical methods have provided detailed insights into its conformational dynamics and have helped elucidate the relationships between its chemical structure and biological activity.

Preclinical studies have shown that ICI 199441 possesses favorable pharmacokinetic properties, including good oral bioavailability and a reasonable half-life. These characteristics make it an attractive candidate for further development into a clinical drug. Additionally, preliminary toxicity studies have indicated that this compound is well-tolerated at therapeutic doses, suggesting a low risk of adverse effects. These encouraging results have prompted researchers to initiate clinical trials to evaluate its safety and efficacy in human subjects.

The impact of CAS No 115199-84-3 on drug discovery extends beyond its immediate therapeutic applications. Its unique chemical structure has inspired new methodologies for designing molecules with enhanced binding affinity and selectivity. By leveraging computational modeling and structure-based drug design techniques, scientists have been able to optimize the pharmacological properties of this compound. These efforts have led to the identification of several derivatives with improved efficacy and reduced side effects.

In conclusion, ICI 199441, identified by CAS No 115199-84-3, represents a significant breakthrough in pharmaceutical chemistry. Its complex molecular architecture and diverse biological activities make it a promising candidate for the treatment of various diseases. Ongoing research efforts are focused on further refining its pharmacological profile and translating these findings into clinical applications. As our understanding of this compound continues to grow, it is likely that it will play an increasingly important role in the development of novel therapeutics for human health.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)